Exosome Diagnostics
Exosome Diagnostics’ non-invasive, exosome-based urine test known as the ExoDx™ Prostate test, or EPI, is a commercially available risk assessment tool for detection of high-grade prostate cancer in men considering prostate biopsy. It is currently available as a laboratory developed test (LDT) through urologists and will soon be offered as CE-IVD in Europe. The test achieved FDA Breakthrough Device designation, is included in the National Comprehensive Cancer Network (NCCN) May 2019 guidelines, received a 10-year unlimited General Services Administration Award, and received a positive Medicare coverage decision....
More Info Less Info